Drug intelligence / Profile preview

lactobacillus rhamnosus + lactobacillus plantarum + lactobacillus crispatus

Development stage: Preclinical
Lead developer: Archer Daniels Midland
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This is an oral probiotic supplement containing a combination of three specific bacterial strains: *Lactobacillus rhamnosus* BPL205, *Lactobacillus plantarum* BPL207, and *Lactobacillus crispatus* BPL209, often supplemented with vitamin D. [13] Developed by ADM/Biopolis, this product is a live biotherapeutic designed to restore vaginal health by normalizing the vaginal microbiome. [2, 6] The probiotic works by colonizing the gut and vaginal microbiomes, where the bacteria produce lactic acid and other antimicrobial substances. [15, 17] This lowers the vaginal pH and inhibits the growth of pathogenic microorganisms, helping to resolve conditions like bacterial vaginosis and vaginal dysbiosis. A pilot study known as PROSALVAG demonstrated that daily oral supplementation could restore a healthy vaginal pH and a Lactobacillus-predominant flora in women with vaginal dysbiosis. [3, 13]

Beyond the preview

Go deeper on lactobacillus rhamnosus + lactobacillus plantarum + lactobacillus crispatus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus rhamnosus + lactobacillus plantarum + lactobacillus crispatus.

Explore the full profile